Select Language
COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global tumor ablation market reached a value of US$ 920 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 1,900 Million by 2027, exhibiting a CAGR of 12.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Tumor ablation refers to a minimally invasive (MI) technique that is conducted to treat tumors of the kidney, liver, bones and lungs. The ablation system consists of a generator and a needlelike device that delivers the heat directly to the target cells to cause acute cellular necrosis. The procedure destroys benign tumors by inserting a probe and heating it to 100-degree Celsius under Precise Computer Tomography, without extracting them from the body. It can be conducted through Microwave Ablation, Radiofrequency Ablation, Cryoablation, etc. It provides increased accuracy and covers a larger treatment area, along with minimal pain and risk to the patient upon repeated administrations.
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
The increasing prevalence of cancer is one of the key factors driving the growth of the market. Furthermore, owing to benefits such as the lesser amount of trauma, speedy recovery, reduced complications and shorter hospital stay, MI procedures are gaining widespread preference, which, in turn, is driving the market growth. Also, various technological advancements such as the introduction of thermal and laser ablation, irreversible electroporation and High-Intensity Focused Ultrasound (HIFU) have enhanced the acceptance of tumor ablation procedures. Moreover, the implementation of favorable government policies for cancer awareness and treatment methods is also creating a positive outlook for the market. Other factors driving the market include growing healthcare expenditures and rising geriatric population, along with the increasing number of ablation and surgical centers and awareness for ablation procedures that can be conducted over small tumors.
IMARC Group provides an analysis of the key trends in each sub-segment of the global tumor ablation market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on technology, mode of treatment, mode of application and end-user.
Breakup by Technology:
www.imarcgroup.com
Note: Values and trends in the above chart consists of dummy data and are only shown here for representation purpose. Kindly contact us for the actual market size and trends.
To get more information about this market, Request Sample
Breakup by Mode of Treatment:
Breakup by Mode of Application:
Breakup by End-User:
Breakup by Region:
www.imarcgroup.com
To get more information on the regional analysis of this market, Request Sample
The report has also analysed the competitive landscape of the market with some of the key players being Medtronic Public Limited Company, AngioDynamics, Inc., HealthTronics, Inc., NeuWave Medical, Inc., INTIO, Inc., Galil Medical Ltd., Boston Scientific Corporation, SonaCare Medical, LLC, EDAP TMS S.A., Erbe Elektromedizin GmbH, IceCure Medical Ltd., MISONIX Inc., Endocare Inc., CooperSurgical Inc. and B V M Meditech Pvt.
| Report Features | Details |
|---|---|
| Base Year of the Analysis | 2021 |
| Historical Period | 2016-2021 |
| Forecast Period | 2022-2027 |
| Units | US$ Million |
| Segment Coverage | Technology, Mode of Treatment, Mode of Application, End-User, Region |
| Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Companies Covered | Medtronic Public Limited Company, AngioDynamics, Inc., HealthTronics, Inc., NeuWave Medical, Inc., INTIO, Inc., Galil Medical Ltd., Boston Scientific Corporation, SonaCare Medical, LLC, EDAP TMS S.A., Erbe Elektromedizin GmbH, IceCure Medical Ltd., MISONIX Inc., Endocare Inc., CooperSurgical Inc. and B V M Meditech Pvt. |
| Customization Scope | 10% Free Customization |
| Report Price and Purchase Option | Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499 |
| Post-Sale Analyst Support | 10-12 Weeks |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
The global tumor ablation market was valued at US$ 920 Million in 2021.
We expect the global tumor ablation market to exhibit a CAGR of 12.7% during 2022-2027.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective treatment for tumors of the kidney, liver, bones, and lungs to reduce the risk of coronavirus infection upon hospital visits or interaction with healthcare professionals and medical equipment.
The rising prevalence of cancer, along with the growing awareness towards numerous benefits offered by MI procedures, such as speedy recovery, less trauma, and reduced complications, is primarily driving the global tumor ablation market.
Based on the technology, the global tumor ablation market has been segmented into Radiofrequency (RF) ablation, microwave ablation, cryoablation, and others. Currently, Radiofrequency (RF) ablation holds the majority of the total market share.
Based on the mode of treatment, the global tumor ablation market can be divided into percutaneous ablation, laparoscopic ablation, and surgical ablation, where surgical ablation currently exhibits a clear dominance in the market.
Based on the mode of application, the global tumor ablation market has been categorized into liver cancer, lung cancer, kidney cancer, bone metastasis, and others. Currently, liver cancer accounts for the largest market share.
Based on the end-user, the global tumor ablation market can be segregated into hospitals, cancer specialty clinics, and others. Among these, hospitals exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.
Some of the major players in the global tumor ablation market include Medtronic Public Limited Company, AngioDynamics, Inc., HealthTronics, Inc., NeuWave Medical, Inc., INTIO, Inc., Galil Medical Ltd., Boston Scientific Corporation, SonaCare Medical, LLC, EDAP TMS S.A., Erbe Elektromedizin GmbH, IceCure Medical Ltd., MISONIX Inc., Endocare Inc., CooperSurgical Inc., and B V M Meditech Pvt.
10% Free customization
Purchase Options
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at
sales@imarcgroup.com